Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
ARDS

ARDS - Aridis Pharmaceuticals Inc Stock Price, Fair Value and News

0.08USD+0.01 (+14.29%)Market Closed
Watchlist

Market Summary

USD0.08+0.01
Market Closed
14.29%

ARDS Stock Price

View Fullscreen

ARDS RSI Chart

ARDS Valuation

Market Cap

3.6M

Price/Earnings (Trailing)

-3.12

Price/Sales (Trailing)

1.9

Price/Free Cashflow

-0.2

ARDS Price/Sales (Trailing)

ARDS Profitability

Return on Equity

-0.67%

Return on Assets

-17.48%

Free Cashflow Yield

-501.55%

ARDS Fundamentals

ARDS Revenue

Rev. Growth (Yr)

4.51%

Rev. Growth (Qtr)

-97.88%

ARDS Earnings

Earnings (TTM)

-1.1M

Earnings Growth (Yr)

98.99%

Earnings Growth (Qtr)

-100.68%

Breaking Down ARDS Revenue

Last 90 days

-22.2%

Trailing 12 Months

-88.3%

How does ARDS drawdown profile look like?

ARDS Financial Health

Current Ratio

0.24

ARDS Investor Care

Shares Dilution (1Y)

151.81%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20230000
20224.4M4.6M1.9M0
20211.8M2.6M3.3M4.1M
20201.0M1.0M1.0M1.0M
20193.5M3.4M2.4M1.0M
20181.3M1.8M2.3M2.8M
2017000860.0K

Tracking the Latest Insider Buys and Sells of Aridis Pharmaceuticals Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 05, 2023
hamilton john f
acquired
-
-
5,000
-
Jun 05, 2023
kurland fred
acquired
-
-
4,000
cfo
Jun 05, 2023
windham-bannister susan richards
acquired
-
-
5,000
-
Jun 05, 2023
patzer eric
acquired
-
-
12,000
executive chairman
Jun 05, 2023
truong vu
acquired
-
-
15,000
ceo and director
Jun 05, 2023
jafri hasan
acquired
-
-
10,000
chief medical officer
Sep 07, 2021
jafri hasan
bought
8,659
4.14139
2,091
chief medical officer
Sep 03, 2021
jafri hasan
bought
12,487
4.15
3,009
chief medical officer
Jul 27, 2021
hamilton john f
bought
9,740
4.87
2,000
-
Jul 27, 2021
patzer eric
bought
25,047
4.84
5,175
-

1–10 of 12

Which funds bought or sold ARDS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 14, 2024
Wealth Architects, LLC
sold off
-100
-1,437
-
-%
Feb 14, 2024
BARTLETT & CO. WEALTH MANAGEMENT LLC
new
-
10.00
10.00
-%
Jan 08, 2024
Bartlett & Co. LLC
new
-
-
-
-%
Nov 15, 2023
Virtu Financial LLC
sold off
-100
-3,000
-
-%
Nov 13, 2023
ICA Group Wealth Management, LLC
sold off
-100
-55.00
-
-%
Sep 09, 2022
B. Riley Wealth Management, Inc.
new
-
11.00
11.00
-%
Jul 12, 2022
Minot Wealth Management LLC
unchanged
-
-33,000
55,000
0.01%

1–7 of 7

Are Funds Buying or Selling ARDS?

Are funds buying ARDS calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ARDS
No. of Funds

Unveiling Aridis Pharmaceuticals Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
armistice capital, llc
9.99%
4,626,190
SC 13G/A
Feb 13, 2024
lind global fund ii lp
0%
0
SC 13G/A
Mar 20, 2023
lind global fund ii lp
8.3%
3e+06
SC 13G
Feb 14, 2023
armistice capital, llc
9.99%
2,997,111
SC 13G
Feb 10, 2023
astrazeneca plc
3.4%
884,956
SC 13G/A
Dec 19, 2022
cystic fibrosis foundation
19.9%
5,168,732
SC 13G
Feb 14, 2022
francis capital management, llc
1.0%
142,838
SC 13G/A
Jul 27, 2021
astrazeneca plc
7.3%
884,956
SC 13G
Apr 01, 2021
francis capital management, llc
6.1%
676,859
SC 13G

Recent SEC filings of Aridis Pharmaceuticals Inc

View All Filings
Date Filed Form Type Document
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 13, 2024
SC 13G/A
Major Ownership Report
Jan 16, 2024
8-K
Current Report
Dec 18, 2023
DEFA14A
DEFA14A
Dec 18, 2023
8-K
Current Report
Dec 15, 2023
DEFA14A
DEFA14A

Peers (Alternatives to Aridis Pharmaceuticals Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
37.9B
9.1B
-16.59% -47.80%
-10.94
4.16
-57.36% -129.46%
32.0B
-
-0.77% 465779.94%
-3.7K
218.4K
- -102.45%
20.5B
1.8B
-23.99% -31.71%
-46.58
11.22
76.23% 61.08%
16.9B
2.3B
-4.89% -18.90%
115.27
7.33
15.05% 75.21%
13.7B
3.7B
-7.62% -26.87%
22.88
3.7
8.87% 75.42%
MID-CAP
8.0B
272.9M
-2.06% 34.31%
-13.22
29.35
141.38% 4.43%
6.5B
-
-3.85% 226.12%
-10.45
60.35
54.84% -25.61%
4.1B
631.9M
-12.60% 32.37%
-27.42
6.46
23.54% 31.53%
3.8B
223.4M
8.92% 47.81%
-18.87
17.04
-35.86% -26.24%
3.7B
240.7M
-19.08% -10.99%
-12.61
15.54
-1.03% -92.09%
SMALL-CAP
1.5B
348.4M
-3.38% -9.50%
23.89
4.25
81.69% -7.29%
579.7M
1.0B
-9.17% -57.89%
-1.06
0.55
-43.15% 58.48%
174.3M
4.9M
-14.18% -58.18%
-1.06
35.65
-57.57% 50.48%
112.6M
881.7K
289.54% 381.25%
-2.37
112.79
-77.61% -13.74%
4.2M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Aridis Pharmaceuticals Inc News

Latest updates
Yahoo Finance3 months ago

Aridis Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue-97.9%41719,6471,0827413992921,187-3,1412,0941,047--1,000500---1,0221,3901,022
Costs and Expenses----8,6337,8118,0298,6119,53921,5416,2676,8995,8235,7925,2306,5565,6897,3958,2668,7596,9687,642
Operating Expenses-78.5%1,2865,9787,345-7,8118,0298,611--------------
  S&GA Expenses-15.2%1,1111,3101,8141,6261,6931,6812,1611,9731,6991,6941,9441,5921,6311,5831,6391,3881,3841,6131,6411,386735
  R&D Expenses-96.3%1754,6685,531-13,4166,1186,3486,4507,56619,8424,5734,9554,2314,1613,6474,9174,3016,0116,6537,1185,5826,907
Income Taxes-100.0%-7.001.0014.003.00---------2.00---2.001.00-
Net Income-100.7%-83.0012,144-6,816-6,387-8,239-7,979-7,766-8,810-21,002-5,490-6,891-5,823-5,786-4,220-6,504-5,648-7,587-8,383-8,063-5,438-7,909
Net Income Margin87.7%-0.61*-4.95*-15.67*-16.17*-17.46*-9.86*-9.85*-10.22*-11.72*-9.36*-12.75*-22.33*-22.04*-23.70*-------
Free Cashflow76.5%-1,032-4,392-4,051-8,606-4,265-6,151-10,187-3,686-8,707-6,731-4,342-5,429-5,600-5,227-------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets0.8%7.006.009.0015.0012.0017.0024.0027.0026.0011.0018.0015.0012.0018.0022.0028.0034.0016.0023.0032.0039.00
  Current Assets5.8%4.004.007.0012.009.0013.0020.0024.0024.009.0015.0013.0010.0016.0020.0026.0031.0013.0021.0028.0036.00
    Cash Equivalents84.2%0.000.001.005.003.008.0014.0020.0019.004.0011.009.006.0012.0016.0021.0017.009.0016.0024.0034.00
  Net PPE-10.2%1.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.001.00
Liabilities-14.3%18.0021.0037.0039.0045.0042.0043.0040.0030.0025.0026.0024.0023.0024.0024.0024.0026.005.005.005.007.00
  Current Liabilities-14.3%17.0020.0035.0037.0042.0039.0036.0033.0029.0024.0025.0022.0018.0019.0019.0019.009.005.005.005.007.00
Shareholder's Equity1.1%1711691691661531531531521521221211141061051054.009.0011.0019.0026.0031.00
  Retained Earnings0.0%-190-190-202-195-186-180-172-165-156-135-129-123-117-111-107-100-95.12-87.53-79.15-71.09-65.65
  Additional Paid-In Capital1.1%17116916916615315315315215212212111410610510510410498.0098.0097.0097.00
Shares Outstanding23.6%45.0036.0036.0027.0018.0018.0018.0012.0012.0011.0010.0010.009.009.00-------
Float------12.00---73.00---50.00---59.00---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations77.4%-983-4,343-4,002-8,557-4,265-6,139-10,166-3,729-8,593-6,607-4,007-5,095-5,584-5,223-4,5743,6703,870-7,885-7,814-8,850-4,714
  Share Based Compensation-4.8%2002102453183493454675515805535675665625234771,00016.0033.0045073233.00
Cashflow From Investing-----49.00--12.00-21.0043.00-114-124-335-334-16.00-4.00-13.00-121-26.0093.00-120-1,000242
Cashflow From Financing-67.0%9993,02826311,032-554-1394,4434,95123,336-1496,5827,949-71514.0018.004,967-8.0010.00-

ARDS Income Statement

2023-09-30
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenue:    
Total revenue$ 417$ 399$ 21,146$ 1,878
Operating expenses:    
Research and development1756,11810,37418,916
General and administrative1,1111,6934,2355,535
Total operating expenses1,2867,81114,60924,451
(Loss) income from operations(869)(7,412)6,537(22,573)
Other income (expense):    
Interest income (expense), net1(27)31(267)
Other income26237768
Change in fair value of note payable759(823)(1,400)(1,212)
Net income (loss)$ (83)$ (8,239)$ 5,245$ (23,984)
Earnings (net loss) per share:    
Basic$ 0.00$ (0.47)$ 0.15$ (1.35)
Diluted$ 0.00$ (0.47)$ 0.11$ (1.35)
Weighted-average common shares outstanding used in computing net loss per share available to common stockholders:    
Basic37,428,94317,701,59235,562,12917,701,592
Diluted37,428,94317,701,59247,178,96717,701,592
Other comprehensive (loss) income$ 1,261$ 2,736
Total comprehensive income (loss)1,178(8,239)7,981(23,984)
Grant [Member]    
Revenue:    
Total revenue4173991,5441,878
License [Member]    
Revenue:    
Total revenue$ 19,602

ARDS Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 35$ 4,876
Restricted cash183
Accounts receivable4171,000
Other receivables100240
Contract costs1,986
Prepaid asset3,5583,341
Total current assets4,11011,626
Property and equipment, net511730
Right-of-use assets, net1,0731,417
Intangible assets, net1317
Restricted cash, non-current500500
Contract costs, non-current78
Other assets327327
Total assets6,53414,695
Current liabilities:  
Accounts payable5,4102,308
Accrued liabilities7,6919,564
Lease liabilities576538
Contract liabilities38020,173
Note payable519
Note payable (at fair value)3,4103,781
Other liabilities1515
Total current liabilities17,48236,898
Contract liabilities, non-current737
Lease liabilities, non-current8541,292
Total liabilities18,33638,927
Stockholders’ deficit:  
Preferred stock (par value $0.0001; 60,000,000 shares authorized; zero shares issued and outstanding as of September 30, 2023 and December 31, 2022)
Common stock (par value $0.0001; 100,000,000 shares authorized; 44,574,021 and 27,033,532 shares issued and outstanding as of September 30, 2023 and December 31, 2022)53
Additional paid-in capital170,827166,380
Accumulated other comprehensive income7,7875,051
Accumulated deficit(190,421)(195,666)
Total stockholders’ deficit(11,802)(24,232)
Total liabilities and stockholders’ deficit$ 6,534$ 14,695
ARDS
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. The company was founded in 2003 and is headquartered in Los Gatos, California.
 CEO
 WEBSITEwww.aridispharma.com
 EMPLOYEES37

Aridis Pharmaceuticals Inc Frequently Asked Questions


What is the ticker symbol for Aridis Pharmaceuticals Inc? What does ARDS stand for in stocks?

ARDS is the stock ticker symbol of Aridis Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aridis Pharmaceuticals Inc (ARDS)?

As of Thu Feb 22 2024, market cap of Aridis Pharmaceuticals Inc is 3.57 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ARDS stock?

You can check ARDS's fair value in chart for subscribers.

What is the fair value of ARDS stock?

You can check ARDS's fair value in chart for subscribers. The fair value of Aridis Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Aridis Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ARDS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Aridis Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether ARDS is over valued or under valued. Whether Aridis Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Aridis Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ARDS.

What is Aridis Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Feb 22 2024, ARDS's PE ratio (Price to Earnings) is -3.12 and Price to Sales (PS) ratio is 1.9. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ARDS PE ratio will change depending on the future growth rate expectations of investors.